Work Package 1 - Derive transgene-free hiPSC lines via SOP-based protocols - hiPSC line characterisation - Reporter line engineering for in situ tracing - hiPSC line cryopreservation, banking and distribution [...] - hiPSC suspension culture and mass expansion in controlled bioreactors including cardiomyogenic differentiation - Induction, characterisation and mass production of cardiac micro tissues - hiPSC suspension
Package 3 - OVIZIO and MHH assess the properties of hiPSC aggregates with OVIZIO‘s holographic microscopy - Comparison of label-free assessment of entire 3D hiPSC aggregates in real time (4D) to gold standards
, dreidimensionale Mikrogewebemodelle, die aus menschlichen induziert pluripotenten Stammzellen (hiPSC) gewonnen werden und, die die Eigenschaften der tiefen Atemwege in vitro nachbilden. Mit Hilfe dieser [...] Geschlecht und epigenetischer Regulation im Vergleich korreliert werden. Diese patientenspezifischen, hiPSC abgeleiteten Lungenorganoide stellen weiterhin eine translationale Plattform zur Wirkstofftestung
recent progress in i) human induced pluripotent stem cell (hiPSC) reprogramming and tailored genetic engineering (RG Martin), ii) novel methods for hiPSC mass production in controlled bioreactors including cardiac
of cardiac endothelial cells - Generation of vascularised cardiac microtissues Work Package 6 - hiPSC differentiation into cardiac ECs and PCs in suspension culture - EC production from reporter lines
beta-cells – for the treatment of diabetes Main tasks Work Package 2 - Development of serum free-based hiPSC suspension culture in stirred tank 100 ml bioreactor - Establishing SOPs under GMP standards for the
live-threatening arrhythmias in the recipient heat, thus raising a key safety concern. Work Packages WP 1 hiPSC derivation and engineering WP 2 Process development at GMP standards WP 3 Bioreactor tools and monitoring
objectives of the project. Main Objectives 1) Advance bioprocesses for therapeutic scale production of hiPSC and their functional cardiac progenies through innovative bioreactor technologies, process optimisation
alternative Zellquelle zu den limitierten primären ECs sind humane induzierte pluripotente Stammzellen (hiPSC). Diese Zellen werden durch die sogenannte Reprogrammierung von Körperzellen hergestellt und sind
RNA pulldown RNA FISH IncRNA library approaches (shRNA, CRISPR/Cas9) genome editing (CRISPR/Cas9) hiPSC generation, culture and cardiomyocyte differentiation AAV-mediated gene expression (gene therapy)